Federal health officials are now focusing on telehealth companies that promote unofficial versions of prescription drugs, especially popular weight loss medications. This move is part of a broader effort by the Trump administration to regulate pharmaceutical advertising more strictly.
Recently, the Food and Drug Administration (FDA) sent over 100 warning letters to various online prescribing companies, including Hims & Hers, which has made a fortune selling cheaper alternatives to well-known obesity treatments like Wegovy and Ozempic. The FDA is concerned that Hims claims its products have “the same active ingredient” as these approved medications when they actually do not. These products come from specialty compounding pharmacies, which the FDA does not review.
The FDA’s warning letter emphasized that the company should clarify that its products are not the same as FDA-approved alternatives. In response, Hims stated that they look forward to an open dialogue with the FDA and highlighted that their materials already indicate these compounded treatments are not FDA-approved.
This marks the FDA’s first serious attempt to oversee online health platforms, which have often claimed immunity from traditional drug advertising rules. Additionally, the FDA took issue with an infomercial featuring Oprah Winfrey, claiming it misleadingly portrayed the safety of GLP-1 drugs, which have serious potential side effects.
Health Secretary Robert F. Kennedy Jr. has been vocal about his disapproval of the pharmaceutical industry and GLP-1 medications. He suggests that obesity can often be managed through lifestyle changes alone. Recently, President Trump directed the FDA to ensure that all pharmaceutical advertising across platforms is “truthful and non-misleading.”
The recent tactic of including “cease and desist” language in FDA letters is significant. This is a departure from the agency’s usual bureaucratic language, indicating a more aggressive stance on misinformation.
Hims has faced scrutiny before, especially following a Super Bowl ad that touted its weight-loss products without mentioning potential side effects. This lack of balance in advertising has drawn criticism from health experts. Dr. Marty Makary called it a “brazen” example of how misleading ads contribute to a culture overly reliant on pharmaceuticals.
Initially, Hims marketed affordable versions of medications for issues like hair loss and erectile dysfunction. However, the surge in demand for weight-loss treatments opened new avenues for these companies to create and sell alternative options.
The FDA allows the compounding of medications when official versions are unavailable, but it recently declared that GLP-1 drugs no longer qualify as scarce. Still, compounding is allowed if a prescription is customized for a patient, which some firms are now promoting as personalized care.
As a result of this scrutiny, shares of Hims & Hers dropped over 6% following the FDA’s announcements. Last week, the FDA’s vaccine division also criticized an ad for AstraZeneca’s FluMist for being distracting and failing to properly address side effects.
This ongoing conversation reflects a larger trend. Researchers and consumer advocates warn that upbeat advertising often obscures critical discussions about medication risks. Studies indicate that exposure to drug ads often leads patients to inquire about medications that may not be suitable for them. The American Medical Association previously supported a ban on such advertising, citing its role in driving demand for costly drugs.
In this ever-evolving landscape of telehealth and pharmaceuticals, it’s clear that transparency and honesty in advertising will be essential to safeguard public health. The FDA’s recent actions signal a shift towards stricter oversight, aiming to ensure that consumers receive accurate information amidst a flood of often misleading advertisements.
Source link
U.S. Food and Drug Administration, Medication, Government regulations, Weight management, General news, Donald Trump, Business, Robert F. Kennedy Jr., Health, Hims Hers Health, Inc., Vinay Prasad, Oprah Winfrey, District of Columbia, Washington news, Novo Nordisk AS, AstraZeneca PLC
